CSL, Talecris Call Off $3.1B Deal Amid FTC Pressure

Law360, New York (June 8, 2009, 12:00 AM EDT) -- CSL Ltd. has called off its proposed $3.1 billion acquisition of rival Talecris Biotherapeutics in the face of allegations by the Federal Trade Commission that the deal would have reduced competition in the U.S. market for plasma-derivative protein therapies.

CSL and Talecris announced Monday that the two companies had agreed to halt the merger, less than two weeks after the FTC filed an administrative complaint and civil lawsuit against CSL and Talecris' parent, Cerberus-Plasma Holdings LLC.

"As we have previously stated we fundamentally disagree with the...
To view the full article, register now.